Nitro Oxide Inhalation Continued With Sildenafil on Neonatal Persistent Pulmonary Hypertension

• Status: Unknown status
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Nitro Oxide (NO) inhalation was recognized as an effect treatment of Neonatal Persistent Pulmonary Hypertension (PPHN), while the safety of NO long term application was under investigation. Several research suggested too much NO2 was generated in the lung after long term (> 72h) use of NO inhalation, which cause bad effects on PS production.

Sildenafil was proved to be effective to PPHN as NO. This medication has a similar clinical effect but need monitoring of blood pressure. The possible hypotension effect restrict the dosage of sildenafil, which limit the usage of sildenafil in severe PPHN. But we recommend sildenafil to The purpose of the study was to establish if NO continued with sildenafil has the same effect as single NO inhalation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Third Military Medical University
• Collaborator: National Natural Science Foundation of China
• Treatments: Sildenafil Citrate

Criteria

Inclusion Criteria:Diagnosed as PPHN in the NICU,primary disease:neonate respiratory distress syndrome,meconium aspiration syndrome of newborn,severe neonatal infectious pneumonia.

• Pulmonary artery pressure > 50mmHg

• mechanical ventilation over 48h

• primary OI(PO2/FiO2)<300

• difference of SpO2 between up and low limbs > 10%

• high FiO2 oxygen inhalation test: positive

Exclusion Criteria:

• congenital heart disease

• diaphragmatic hernia